References
- Knochenhauer E S, Key T J, Kahsar-Miller M, Waggoner W, Boots L R, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078–3082
- Dahlgren E, Janson P O, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992; 71: 599–604
- Dahlgren E, Janson P O, Johansson S, Lapidus L, Lindstedt G, Tengborn L. Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril 1994; 61: 455–460
- Wild R A. Poyicystic ovary syndrome: a risk for coronary artery disease?. Am J Obstet Gynecol 2002; 186: 35–43
- DeLoughery T G. Coagulation abnormalities and cardiovascular disease. Curr Opin Lipidol 1999; 10: 443–448
- Thompson S G, Kienast J, Pyke S D, Haverkate F, van de Loo J C. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Eng J Med 1995; 332: 635–641
- Glueck C J, Wang P, Fontaine R N, Sieve-Smith L, Tracy T, Moore S K. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999; 48: 1589–1595
- Sampson M, Kong C, Patel A, Unwin R, Jacobs H S. Ambulatory blood pressure profiles and plasminogen activator inhibitor activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1996; 45: 623–629
- Atiomo W U, Bates S A, Condon J E, Shaw S, West J H, Prentice A G. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 1998; 69: 236–241
- Brakman P, Albrechtsen O K, Astrup T. A comparative study of coagulation and fibrinolysis in blood from normal men and women. Br J Haematol 1966; 12: 74–85
- Yildiz B O, Haznedaroglu I C, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab 2002; 87: 3871–3875
- Winkler U H. Effects of androgens on haemostasis. Maturitas 1996; 24: 147–155
- Admiral J, Melmajac A, Gin H, Pannel R, Vissac A M, Seigneur M, Scarabin P Y, Boisseau M, Guize L, Gurewich V. Evaluation of the fibrinolytic potential of plasma: physiological and pathological variations and associations with cardiovascular disease risk factors. Fibrinolysis Proteol 1999; 13: 1–10
- Owens M R, Cimino C D, Donelly J. Testosterone effects on biosynthesis of coagulation proteins. Thromb Haemost 1987; 57: 259–262
- Buckler H M, McElhone K, Durrington P N, Mackness M I, Ludlam C A, Wu F CW. The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women. Clin Endocrinol (Oxf) 1997; 49: 173–178
- Van Wersch J WJ, Ubachs J MH, Van den Ende A, Van Enk A. The effect of two regimens of hormone replacement therapy on the haemostatic profile in postmenopausal women. Eur J Clin Chem Clin Biochem 1994; 32: 449–453